Journal article
Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.
Abstract
149
Background: Cell-free ctDNA may be prognostic and evolve following therapy. We report ctDNA profiling of patients (pts) with mCRPC and their association with clinical outcomes and evolution with therapy. Methods: Pts with mCRPC that underwent baseline ctDNA analysis for potentially actionable alterations using Guardant360 before new systemic therapy were identified. Data were requested for clinical factors, current and …
Authors
Sonpavde G; Nagy RJ; Sartor AO; Pond GR; Gourdin TS; Nandagopal L; Ledet EM; Agarwal N; Carroll E; Naik G
Journal
Journal of Clinical Oncology, Vol. 35, No. 6_suppl, pp. 149–149
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2017
DOI
10.1200/jco.2017.35.6_suppl.149
ISSN
0732-183X